Eutelsat Communications


HEALTH OPTIONS

09/06/20 -"Once the darling of COVID-19 lockdown times, the Health sector (ex Pharma) has gone into reverse now that the risk needle has moved by 180°. Sure enough for the contrarians in us, this opens up ..."

Pages
65
Language
English
Published on
09/06/20
You may also be interested by these reports :
21/03/24
No surprise: 2023 revenues were up by 5% yoy and EBITDA by 2.2%. The EBITDA margin of the Consumer Access segment was effectively 16% in 2023 vs ...

20/03/24
Following the presentation, in parallel to the preliminary 2023 results. of the 2024-26 plan excluding Netco (the fixed network infrastructure assets ...

18/03/24
DT’s share price had been going nowhere for six years between 2015 and 2021 (ranging between €13 and €16) but since the merger of T-Mobile US with ...

13/03/24
SES published FY 23 results with flat revenues at €2,030m along with adjusted EBITDA of €1,025m down by -7.3% YOY due to a sudden undisclosed ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO